A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Summary

The purpose of this study was to determine whether a fixed dose combination of indacaterol and glycopyrronium (QVA149) has an impact on night-time blood oxygen levels in Chronic Obstructive Pulmonary Disease.

Timeline

Start

2014-11-30

Primary completion

2016-06-26

Completion

2016-06-26

Outcome

Missed primary endpoint

registry QVA149 (Indacaterol/Glycopyrronium) vs Placebo; p = 0.2419; Mean Difference (Net) -0.44 (95% CI -1.21 to 0.32) NCT02233543 ↗

Drugs

Indications